Incorporate sample size proportionate with each indication: CDSCO Panel Tells Sun Pharma on Ranibizumab study

Ranibizumab binds to VEGF-A with high affinity as well as its biologically active forms, such as VEGF165, VEGF121, and VEGF110. Notably, VEGF165 is the most predominant isoform in the human eye that promotes ocular neovascularization. VEGF165 enhances vascular permeability, inhibits apoptosis, and causes endothelial-cell mobilization from the bone marrow and differentiation for angiogenesis. Ranibizumab binds to the receptor-binding site of VEGF-A, preventing it from binding to its receptors - VEGFR1 and VEGFR2 - that are expressed on the surface of endothelial cells. Ranibizumab thereby attenuates endothelial cell proliferation, vascular leakage, and new blood vessel formation.

At the recent SEC meeting for Ophthalmology held on 22nd May 2024, the expert panel reviewed the proposal for permission to conduct a Phase IV study titled “A prospective, multicenter, single-arm, Phase IV study to assess the safety, efficacy, and immunogenicity of Ranibizumab solution for injection 10 mg/mL (rDNA Origin) vide protocol No. ICR/23/004, version No. 2.0 dated 05.04.2024."

After detailed deliberation, the committee recommended incorporating the sample size proportionate with each indication in the study.

Accordingly, the expert panel suggested that the firm should submit the revised protocol to CDSCO for further deliberation by the committee.

Also Read: CDSCO Drug alert: 50 medicine batches flagged